| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 30, 2025 4:30 P.M. |
| Form: | F-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful convening of its inaugural Annual Scientific Advisory Board (SAB) meeting. This meeting brought together eight world-renowned professors and experts in psychiatry, addiction research, and metabolic disorders to provide strategic guidance on Clearmind's innovative clinical and preclinical programs. A central focus of the SAB discussions was Clearmind's lead candidate,
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities purchase agreements (the "SPAs") with institutional investors (the "Holders"). Pursuant to the SPAs, the Company may issue and sell, from time to time, convertible promissory notes (the "Notes") in an aggregate principal amount of up to $10,000,000. Upon the execution of the SPAs (the "First Initial Closing"), the Company issued and sold to the Hol
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders. The patent application published under the European Patent Office covers an innovative combinatio
EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD su
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind" or "the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board ("SAB"). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is
Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine Tel Aviv, Israel / Vancouver, Canada, March 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Professor Henry R. Kranzler, M.D., as the newest member of its Scientific Advisory Board ("SAB"). Professor Kranzler is the Benjamin Rush Professor of Psychiatry, an
SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)